Evidence map›Paper›PMID 34163421›Full record

ReviewFrontiers in neurology2021

Immunotherapies for Neurodegenerative Diseases.

Ibrahim Mortada, Raymond Farah, Sanaa Nabha, David M Ojcius, Youssef Fares, Wassim Y Almawi, Najwane Said Sadier

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 3 pooled it
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 3 syntheses or guidelines pooled it, 99 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Ibrahim MortadaNeuroscience Research Center, Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon.
Raymond FarahNeuroscience Research Center, Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon.
Sanaa NabhaNeuroscience Research Center, Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon.
David M OjciusDepartment of Biomedical Sciences, University of the Pacific, Arthur Dugoni School of Dentistry, San Francisco, CA, United States.
Youssef FaresNeuroscience Research Center, Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon.
Wassim Y AlmawiCollege of Health Sciences, Abu Dhabi University, Abu Dhabi, United Arab Emirates.
Najwane Said SadierNeuroscience Research Center, Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon.
Lebanese University · LBAbu Dhabi University · AEUniversity of the Pacific · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current treatments for neurodegenerative diseases are mostly symptomatic without affecting the underlying cause of disease. Emerging evidence supports a potential role for immunotherapy in the management of disease progression. Numerous reports raise the exciting prospect that either the immune system or its derivative components could be harnessed to fight the misfolded and aggregated proteins that accumulate in several neurodegenerative diseases. Passive and active vaccinations using monoclonal antibodies and specific antigens that induce adaptive immune responses are currently under evaluation for their potential use in the development of immunotherapies. In this review, we aim to shed light on prominent immunotherapeutic strategies being developed to fight neuroinflammation-induced neurodegeneration, with a focus on innovative immunotherapies such as vaccination therapy.

Indexed as

active immunizationanti-inflammatory agentsimmunotherapyneurodegenerative diseasesneuroinflammationneuropathologypassive immunizationvaccination

Identifiers

PMID34163421
PMCPMC8215715
OpenAlexW3168307942

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.